查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1654139

美国医药第三方物流服务市场规模、份额、趋势分析报告：按产品类型、温度、治疗领域、製造商规模、服务、细分预测，2025-2030 年

U.S. Pharmaceutical Third-party Logistics Services Market Size, Share & Trends Analysis Report By Product Type, By Temperature, By Therapeutic Area, By Manufacturer Size, By Service, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10个工作天内

价格

美国医药第三方物流服务市场的成长与趋势：

根据Grand View Research, Inc.的最新报告，美国医药第三方物流（3PL）服务市场规模预计到2030年将达到754.1亿美元，2025年至2030年期间的复合年增长率为8.90%。

市场对高效、安全的供应链解决方案的需求不断增长、药品分销的复杂性日益增加以及遵守严格的监管标准的需要不断推动。此外，对生技药品和疫苗等温度敏感型特种药品的需求不断增长，推动了低温运输物流的重要性，製药公司转向第三方物流供应商寻求先进的储存和运输解决方案。

此外，先进技术的发展提高了医药物流的效率和安全性，也促进了市场的成长。随着医疗物流业务变得越来越复杂，越来越依赖自动资料报告系统来简化合规性和效能监控。自动彙报解决方案可协助医药第三方物流供应商产生关键绩效指标 (KPI)（例如准时交货率、产品状况和法规遵循）的即时、准确的报告。这些系统还可以自动产生监管机构所需的报告，减少手动工作并确保所有必需的文件按时提交。

此外，对温度敏感的药品和生物製药的需求不断增长，大大刺激了低温运输物流市场的扩张。随着对这些敏感产品的安全储存和运输的需求不断增长，主要企业正在转向创新的低温运输解决方案来保障产品品质和效力。此外，随着人工智慧的融入，科技不断进步，进一步推动了医药产业对低温运输物流的需求。根据《Pharmaceutical Commerce》在2024年10月发表的报导，人工智慧（AI）有可能透过多种变革性的方式改变透过低温运输运输的温度敏感药品的物流。人工智慧可以透过预测分析、即时监控以及路线和资源优化使供应链更加高效和可靠。

市场的主要企业包括 Cencora Corporation、Kuehne+Nagel、Kerry Logistics Network Limited、Cardinal Health、McKesson Corporation 和 Thermo Fisher Scientific。市场参与者正在采取关键策略倡议来增强其市场影响力并扩大业务。例如，2023 年 4 月，Kuehne+Nagel 宣布将在达拉斯-沃斯堡国际机场附近建造一个占地 40 万平方英尺的合约物流履约中心。该设施距离航站楼三英里，彰显了该公司在医疗物流的战略投资，旨在为多个客户提供尖端服务。

美国医药第三方物流服务市场报告重点

  • 根据产品，由于糖尿病、高血压和心血管疾病等慢性疾病的增加，品牌药品领域预计将在 2024 年占据市场主导地位。这些疾病的日益普及导緻美国对品牌药物的需求增加。
  • 依温度划分，2024 年常温占最大销售份额。对于不需要冷藏或冷冻的产品（例如某些口服药物和非处方药物），常温储存至关重要。
  • 根据治疗领域，肿瘤学在 2024 年占据最大的收入份额。随着全国癌症患者数量的增加，该领域的市场可能会扩大。此外，最近的趋势是癌症治疗取得了重大进展，人们对药物的关注度日益提高。
  • 根据製造商规模，大型製造商将在 2024 年占据最大的销售份额。大型製造商拥有丰富的资源和成熟的供应链。这些公司通常拥有庞大的生产能力和广泛的产品系列，这使得他们能够与物流供应商协商出有利的条款。
  • 按服务划分，仓储和运输在 2024 年占据了最大的收入份额。随着竞争格局加剧和流程变得更加复杂，製药公司不断寻找新方法来优化供应链生产力并遵守行业动态，从而导致对 3PL 储存和分销服务的采用增加。

目录

第一章调查方法与范围

第 2 章执行摘要

第 3 章美国医药第三方物流(3PL) 服务市场变数、趋势与范围

  • 市场展望
    • 母市场展望
    • 相关/辅助市场展望。
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 市场分析工具
    • 波特五力分析
    • PESTEL 分析
    • COVID-19影响分析

第 4 章美国医药第三方物流(3PL) 服务市场：产品类型估计与趋势分析

  • 细分仪表板
  • 美国医药第三方物流(3PL) 服务市场：产品类型变化分析
  • 2018 - 2030 年美国医药第三方物流(3PL) 服务规模及趋势分析（依产品类型）
  • 品牌
  • 非专利的
  • 生物相似药
  • 疫苗
  • 细胞疗法
  • 基因治疗
  • 其他的

第五章美国医药第三方物流（3PL）服务市场：温度估计与趋势分析

  • 细分仪表板
  • 美国医药第三者物流(3PL) 服务市场：温度波动分析
  • 2018 年至 2030 年美国医药第三人物流(3PL) 服务规模及温度趋势分析
  • 环境的
  • 冷藏
  • 冷冻
  • 超冷冻/冷冻
  • 低温

第六章美国医药第三方物流(3PL) 服务市场：治疗领域估计与趋势分析

  • 细分仪表板
  • 美国医药第三方物流(3PL) 服务市场：治疗领域变化分析
  • 2018 年至 2030 年美国医药第三方物流(3PL) 服务规模及趋势分析（依治疗领域）
  • 肿瘤学
  • 心血管疾病
  • 感染疾病
  • 神经病学
  • 糖尿病
  • 肾臟科
  • 风湿病学
  • 过敏/气喘
  • 胃肠病学
  • 眼科
  • 其他的

第 7 章：美国医药第三方物流(3PL) 服务市场：製造商规模估计与趋势分析

  • 细分仪表板
  • 美国医药第三方物流(3PL) 服务市场：製造商规模变化分析
  • 2018 年至 2030 年美国医药第三方物流(3PL) 服务规模及趋势分析（依製造商规模）
  • 大的
  • 中等的
  • 小的

第 8 章：美国医药第三方物流(3PL) 服务市场：服务评估与趋势分析

  • 细分仪表板
  • 美国医药第三方物流（3PL）服务市场：服务变化分析
  • 2018 年至 2030 年美国医药第三方物流(3PL) 服务规模与趋势分析（依服务划分）
  • 储存和运输
  • 订单到现金
  • 标题 型号
  • DSCSA 和序列化服务
  • 药品样品
  • 其他的

第九章 竞争格局

  • 公司分类
  • 2024 年企业市场分析
  • 公司简介
    • CEVA Logistics
    • Cencora Corporation（ICS）
    • DB SCHENKER
    • Kuehne+Nagel
    • Kerry Logistics Network Limited
    • Cardinal Health
    • McKesson Corporation
    • EVERSANA.
    • Thermo Fisher Scientific Inc.
    • Knipper Health
Product Code: GVR-4-68040-499-2

U.S. Pharmaceutical Third-party Logistics Services Market Growth & Trends:

The U.S. pharmaceutical third-party logistics services market size is expected to reach USD 75.41 billion by 2030 and it is anticipated to grow at a CAGR of 8.90% from 2025 to 2030, according to a new report by Grand View Research, Inc. The market is driven due to the growing demand for efficient and secure supply chain solutions, increasing complexity in pharmaceutical distribution, and the need for compliance with stringent regulatory standards. Moreover, the rise in demand for temperature-sensitive and specialty drugs, such as biologics and vaccines, has heightened the importance of cold chain logistics, prompting pharmaceutical companies to rely on 3PL providers for advanced storage and transportation solutions.

Furthermore, is the development of advanced technologies to improve the efficiency and security of drug distribution is also contributing to the market growth. As pharmaceutical logistics operations become more complex, there is a growing reliance on automated data reporting systems to streamline compliance and performance monitoring. Automated reporting solutions help pharmaceutical 3PL providers generate real-time, accurate reports on key performance indicators (KPIs) such as on-time delivery rates, product condition, and regulatory compliance. These systems also automate the generation of reports required by regulatory bodies, reducing manual effort and ensuring that all necessary documentation is submitted on time.

In addition, the growing demand for temperature-sensitive pharmaceuticals and biopharmaceuticals is significantly fueling the expansion of the cold chain logistics market. Growing demand for the safe storage and transportation of these delicate products has led the companies to innovative cold chain solutions that safeguard product quality and efficacy. Moreover, increasing technological advancements by integrating artificial intelligence is further boosting the demand for cold chain logistics in the pharmaceutical sector. According to an article published by Pharmaceutical Commerce in October 2024, artificial intelligence (AI) has the potential to revolutionize the logistics of temperature-sensitive pharmaceuticals shipped through the cold chain in several transformative ways. AI can enhance the supply chain's efficiency and reliability through predictive analytics, real-time monitoring, and optimization of routes and resources.

Some of the key players in the market are Cencora Corporation, Kuehne+Nagel, Kerry Logistics Network Limited, Cardinal Health, McKesson Corporation, Thermo Fisher Scientific, among others. Market players are adopting key strategic initiatives to boost their market presence and expand their business. For instance, in April 2023, Kuehne+Nagel announced a 400,000 sq. ft. contract logistics fulfillment center near Dallas/Fort Worth International Airport. Positioned three miles from the terminals, the facility highlighted the company's strategic investment in healthcare logistics, designed to serve multiple clients with state-of-the-art capabilities.

U.S. Pharmaceutical Third-party Logistics Services Market Report Highlights:

  • Based on product, the branded drugs segment dominated the market in 2024 due to growing incidence of chronic diseases such as diabetes, hypertension, and cardiovascular conditions. The increasing cases of these condition have led to the rising demand for branded drugs in the U.S.
  • Based on the temperature, ambient held the largest revenue share in 2024. Ambient storage is essential for products that do not require refrigeration or freezing, such as certain oral medications, over-the-counter drugs, among others.
  • Based on the therapeutic area, oncology held the largest revenue share in 2024. The market for the segment is likely to expand with an increasing number of cancer cases across the country. Furthermore, recent trends have shown a shifting focus towards pharmaceutical products with significant advancements made in the treatment of cancer.
  • Based on the manufacturer size, large held the largest revenue share in 2024. The large manufacturers have extensive resources and established supply chains. These companies typically have significant production capacities and a broad portfolio of products, which allows them to negotiate favorable terms with logistics providers.
  • Based on the service, storage and shipping held the largest revenue share in 2024. With the increasingly competitive business landscape and complex process, several pharmaceutical companies are constantly seeking new ways to optimize their supply chain productivity and ensure compliance with industry regulations, further adopting the 3PL storage and shipping services.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. GVR's Internal Database
    • 1.4.3. Secondary Sources
    • 1.4.4. Primary Research
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
    • 1.6.1. Commodity Flow Analysis
    • 1.6.2. Bottom-up Approach
  • 1.7. List of Secondary Sources
  • 1.8. List of Abbreviations
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. U.S. Pharmaceutical Third-Party Logistics (3PL) Services Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook.
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. The Rise of E-Commerce
      • 3.2.1.2. Growing Demand for Outsourcing Services
      • 3.2.1.3. Rising Demand for Cold Chain Logistics
      • 3.2.1.4. Growing Applications of Reverse Logistics in Biopharmaceutical Industry
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. High Operational Costs
      • 3.2.2.2. Compliance Issues While Outsourcing
  • 3.3. Market Analysis Tools
    • 3.3.1. Porter's Five Forces Analysis
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID-19 Impact Analysis

Chapter 4. U.S. Pharmaceutical Third-Party Logistics (3PL) Services Market: Product Type Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. U.S. Pharmaceutical Third-Party Logistics (3PL) Services Market; Product Type Movement Analysis
  • 4.3. U.S. Pharmaceutical Third-Party Logistics (3PL) Services Size & Trend Analysis, by Product Type, 2018 to 2030 (USD Million)
  • 4.4. Branded
    • 4.4.1. Branded market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5. Generic
    • 4.5.1. Generic market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6. Biosimilar
    • 4.6.1. Biosimilar market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.7. Vaccine
    • 4.7.1. Vaccine market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.8. Cell Therapy
    • 4.8.1. Cell therapy market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.9. Gene Therapy
    • 4.9.1. Gene therapy market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.10. Others
    • 4.10.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. U.S. Pharmaceutical Third-Party Logistics (3PL) Services Market: Temperature Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. U.S. Pharmaceutical Third-Party Logistics (3PL) Services Market; Temperature Movement Analysis
  • 5.3. U.S. Pharmaceutical Third-Party Logistics (3PL) Services Size & Trend Analysis, by Temperature, 2018 to 2030 (USD Million)
  • 5.4. Ambient
    • 5.4.1. Ambient market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5. Refrigerated
    • 5.5.1. Refrigerated market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6. Frozen
    • 5.6.1. Frozen market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.7. Ultra-frozen/Deep-Frozen
    • 5.7.1. Ultra-frozen/Deep-Frozen market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.8. Cryogenic
    • 5.8.1. Cryogenic market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. U.S. Pharmaceutical Third-Party Logistics (3PL) Services Market: Therapeutic Area Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. U.S. Pharmaceutical Third-Party Logistics (3PL) Services Market; Therapeutic Area Movement Analysis
  • 6.3. U.S. Pharmaceutical Third-Party Logistics (3PL) Services Size & Trend Analysis, by Therapeutic Area, 2018 to 2030 (USD Million)
  • 6.4. Oncology
    • 6.4.1. Oncology market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5. Cardiovascular Diseases
    • 6.5.1. Cardiovascular diseases market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Infectious Diseases
    • 6.6.1. Infectious diseases market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7. Neurology
    • 6.7.1. Neurology market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.8. Diabetes
    • 6.8.1. Diabetes market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.9. Nephrology
    • 6.9.1. Nephrology market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.10. Rheumatology
    • 6.10.1. Rheumatology market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.11. Allergy/Asthma
    • 6.11.1. Allergy/Asthma market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.12. Gastroenterology
    • 6.12.1. Gastroenterology market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.13. Ophthalmology
    • 6.13.1. Ophthalmology market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.14. Others
    • 6.14.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. U.S. Pharmaceutical Third-Party Logistics (3PL) Services Market: Manufacturer Size Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. U.S. Pharmaceutical Third-Party Logistics (3PL) Services Market; Manufacturer Size Movement Analysis
  • 7.3. U.S. Pharmaceutical Third-Party Logistics (3PL) Services Size & Trend Analysis, by Manufacturer Size, 2018 to 2030 (USD Million)
  • 7.4. Large
    • 7.4.1. Large market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5. Medium
    • 7.5.1. Medium market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Small
    • 7.6.1. Small market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. U.S. Pharmaceutical Third-Party Logistics (3PL) Services Market: Service Estimates & Trend Analysis

  • 8.1. Segment Dashboard
  • 8.2. U.S. Pharmaceutical Third-Party Logistics (3PL) Services Market; Service Movement Analysis
  • 8.3. U.S. Pharmaceutical Third-Party Logistics (3PL) Services Size & Trend Analysis, by Service, 2018 to 2030 (USD Million)
  • 8.4. Storage and Shipping
    • 8.4.1. Storage and Shipping market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5. Order-to-cash
    • 8.5.1. Order-to-cash market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6. Title Model
    • 8.6.1. Title Model market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7. DSCSA and Serialization Services
    • 8.7.1. DSCSA and Serialization Services market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.8. Pharmaceutical Sampling
    • 8.8.1. Pharmaceutical Sampling market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.9. Others
    • 8.9.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Company Categorization
  • 9.2. Company Market Position Analysis, 2024
  • 9.3. Company Profiles
    • 9.3.1. CEVA Logistics
      • 9.3.1.1. Company overview
      • 9.3.1.2. Financial performance
      • 9.3.1.3. Service benchmarking
      • 9.3.1.4. Strategic initiatives
    • 9.3.2. Cencora Corporation (ICS)
      • 9.3.2.1. Company overview
      • 9.3.2.2. Financial performance
      • 9.3.2.3. Service benchmarking
      • 9.3.2.4. Strategic initiatives
    • 9.3.3. DB SCHENKER
      • 9.3.3.1. Company overview
      • 9.3.3.2. Financial performance
      • 9.3.3.3. Service benchmarking
      • 9.3.3.4. Strategic initiatives
    • 9.3.4. Kuehne+Nagel
      • 9.3.4.1. Company overview
      • 9.3.4.2. Financial performance
      • 9.3.4.3. Service benchmarking
      • 9.3.4.4. Strategic initiatives
    • 9.3.5. Kerry Logistics Network Limited
      • 9.3.5.1. Company overview
      • 9.3.5.2. Financial performance
      • 9.3.5.3. Service benchmarking
      • 9.3.5.4. Strategic initiatives
    • 9.3.6. Cardinal Health
      • 9.3.6.1. Company overview
      • 9.3.6.2. Financial performance
      • 9.3.6.3. Service benchmarking
      • 9.3.6.4. Strategic initiatives
    • 9.3.7. McKesson Corporation
      • 9.3.7.1. Company overview
      • 9.3.7.2. Financial performance
      • 9.3.7.3. Service benchmarking
      • 9.3.7.4. Strategic initiatives
    • 9.3.8. EVERSANA.
      • 9.3.8.1. Company overview
      • 9.3.8.2. Financial performance
      • 9.3.8.3. Service benchmarking
      • 9.3.8.4. Strategic initiatives
    • 9.3.9. Thermo Fisher Scientific Inc.
      • 9.3.9.1. Company overview
      • 9.3.9.2. Financial performance
      • 9.3.9.3. Service benchmarking
      • 9.3.9.4. Strategic initiatives
    • 9.3.10. Knipper Health
      • 9.3.10.1. Company overview
      • 9.3.10.2. Financial performance
      • 9.3.10.3. Service benchmarking
      • 9.3.10.4. Strategic initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 U.S. Pharmaceutical Third-Party Logistics (3PL) Services, by Product Type, 2018 - 2030 (USD Million)
  • Table 4 U.S. Pharmaceutical Third-Party Logistics (3PL) Services, by Temperature, 2018 - 2030 (USD Million)
  • Table 5 U.S. Pharmaceutical Third-Party Logistics (3PL) Services, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 6 U.S. Pharmaceutical Third-Party Logistics (3PL) Services, by Manufacturer Size, 2018 - 2030 (USD Million)
  • Table 7 U.S. Pharmaceutical Third-Party Logistics (3PL) Services, by Service, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Information Procurement
  • Fig. 2 Primary Research Pattern
  • Fig. 3 Market Research Approaches
  • Fig. 4 Value Chain-Based Sizing & Forecasting
  • Fig. 5 Market Formulation & Validation
  • Fig. 6 Pharmaceutical Third-Party Logistics (3PL) Services, Market Segmentation
  • Fig. 7 Market Driver Analysis (Current & Future Impact)
  • Fig. 8 Market Restraint Analysis (Current & Future Impact)
  • Fig. 9 Porter's Five Forces Analysis
  • Fig. 10 PESTEL Analysis
  • Fig. 11 U.S. Pharmaceutical Third-Party Logistics (3PL) Services, for Branded, 2018 - 2030 (USD Million)
  • Fig. 12 U.S Pharmaceutical Third-Party Logistics (3PL) Services, for Generic, 2018 - 2030 (USD Million)
  • Fig. 13 U.S. Pharmaceutical Third-Party Logistics (3PL) Services, for Biosimilar, 2018 - 2030 (USD Million)
  • Fig. 14 U.S. Pharmaceutical Third-Party Logistics (3PL) Services, for Vaccine, 2018 - 2030 (USD Million)
  • Fig. 15 U.S. Pharmaceutical Third-Party Logistics (3PL) Services, for Cell Therapy, 2018 - 2030 (USD Million)
  • Fig. 16 U.S. Pharmaceutical Third-Party Logistics (3PL) Services, for Gene Therapy, 2018 - 2030 (USD Million)
  • Fig. 17 U.S. Pharmaceutical Third-Party Logistics (3PL) Services, for Others, 2018 - 2030 (USD Million)
  • Fig. 18 U.S. Pharmaceutical Third-Party Logistics (3PL) Services, for Ambient, 2018 - 2030 (USD Million)
  • Fig. 19 U.S. Pharmaceutical Third-Party Logistics (3PL) Services, for Refrigerated, 2018 - 2030 (USD Million)
  • Fig. 20 U.S. Pharmaceutical Third-Party Logistics (3PL) Services, for Frozen, 2018 - 2030 (USD Million)
  • Fig. 21 U.S. Pharmaceutical Third-Party Logistics (3PL) Services, for Ultra-frozen/Deep-Frozen, 2018 - 2030 (USD Million)
  • Fig. 22 U.S. Pharmaceutical Third-Party Logistics (3PL) Services, for Cryogenic, 2018 - 2030 (USD Million)
  • Fig. 23 U.S. Pharmaceutical Third-Party Logistics (3PL) Services, for Oncology, 2018 - 2030 (USD Million)
  • Fig. 24 U.S. Pharmaceutical Third-Party Logistics (3PL) Services, for cardiovascular diseases, 2018 - 2030 (USD Million)
  • Fig. 25 U.S. Pharmaceutical Third-Party Logistics (3PL) Services, for Infectious Diseases, 2018 - 2030 (USD Million)
  • Fig. 26 U.S. Pharmaceutical Third-Party Logistics (3PL) Services, for Neurology, 2018 - 2030 (USD Million)
  • Fig. 27 U.S. Pharmaceutical Third-Party Logistics (3PL) Services, for Diabetes, 2018 - 2030 (USD Million)
  • Fig. 28 U.S. Pharmaceutical Third-Party Logistics (3PL) Services, for Nephrology, 2018 - 2030 (USD Million)
  • Fig. 29 U.S. Pharmaceutical Third-Party Logistics (3PL) Services, for Rheumatology, 2018 - 2030 (USD Million)
  • Fig. 30 U.S. Pharmaceutical Third-Party Logistics (3PL) Services, for Allergy/Asthma, 2018 - 2030 (USD Million)
  • Fig. 31 U.S. Pharmaceutical Third-Party Logistics (3PL) Services, for Gastroenterology, 2018 - 2030 (USD Million)
  • Fig. 32 U.S. Pharmaceutical Third-Party Logistics (3PL) Services, for Ophthalmology, 2018 - 2030 (USD Million)
  • Fig. 33 U.S. Pharmaceutical Third-Party Logistics (3PL) Services, for Others, 2018 - 2030 (USD Million)
  • Fig. 34 U.S. Pharmaceutical Third-Party Logistics (3PL) Services, for Large, 2018 - 2030 (USD Million)
  • Fig. 35 U.S. Pharmaceutical Third-Party Logistics (3PL) Services, for Medium, 2018 - 2030 (USD Million)
  • Fig. 36 U.S. Pharmaceutical Third-Party Logistics (3PL) Services, for Small, 2018 - 2030 (USD Million)
  • Fig. 37 U.S. Pharmaceutical Third-Party Logistics (3PL) Services, for Storage and Shipping, 2018 - 2030 (USD Million)
  • Fig. 38 U.S. Pharmaceutical Third-Party Logistics (3PL) Services, for Order-to-cash, 2018 - 2030 (USD Million)
  • Fig. 39 U.S. Pharmaceutical Third-Party Logistics (3PL) Services, for Title Model, 2018 - 2030 (USD Million)
  • Fig. 40 U.S. Pharmaceutical Third-Party Logistics (3PL) Services, for DSCSA and Serialization Services, 2018 - 2030 (USD Million)
  • Fig. 41 U.S. Pharmaceutical Third-Party Logistics (3PL) Services, for Pharmaceutical Sampling, 2018 - 2030 (USD Million)
  • Fig. 42 U.S. Pharmaceutical Third-Party Logistics (3PL) Services, for Others, 2018 - 2030 (USD Million)